Canada announced that it had recorded a second case of blood clot within a week with low platelet levels after receiving the AstraZeneca vaccine against the corona virus, but would keep recommending its use.
On Twitter, health authorities explained that the case was recorded with a person living in Alberta province (West) who received a dose of an AstraZeneca vaccine made in India at the Serum Institute, noting that "the person is being treated and recovering.
A first such case was announced last Tuesday for a woman from Quebec who received the same vaccine.
The authorities said that cases of blood clots associated with low platelet levels after receiving the AstraZeneca vaccine were "still very rare" and Canada continued to "consider that the benefits of vaccines in COVID-19 protection outweigh the potential risks."
In late March, the National Vaccination Advisory Committee recommended suspending the use of the AstraZeneca vaccine in people under the age of 55 to enable risk assessment.
However, health authorities confirmed Wednesday that, according to their analysts, it is not necessary at the moment to limit the use of the vaccine for some people.
The Advisory Committee was studying available data with a view to determining whether or not to change its position.
Canada has recorded more than 1.1 million infections since the outbreak of the Corona epidemic and about 23,500 deaths.